

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Thalidomide

INITIATION

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- The patient has multiple myeloma
- or
- The patient has systemic AL amyloidosis*
- or
- The patient has erythema nodosum leprosum

CONTINUATION

Prerequisites (tick box where appropriate)

- Patient has obtained a response from treatment during the initial approval period

Note: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier
Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen
Indication marked with * is an unapproved indication

I confirm that the above details are correct:

Signed: Date: